Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus reuteri gmnl-89 + lactobacillus plantarum gmnl-141 + lactobacillus paracasei gmnl-133
- Development stage
- Preclinical
- Lead developer
- GenMont Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
This multi-strain probiotic combination, developed by GenMont Biotech, comprises *Lactobacillus reuteri* GMNL-89, *Lactobacillus plantarum* GMNL-141, and *Lactobacillus paracasei* GMNL-133. It is designed as a live biotherapeutic product (LBP) that modulates the host immune system and suppresses systemic inflammation. Preclinical studies in mouse models have demonstrated its potential in treating chronic obstructive pulmonary disease (COPD) by reducing the levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, and in inhibiting the progression of pancreatic ductal adenocarcinoma (PDAC) when used as an adjuvant therapy. The individual strains are also associated with improvements in allergic diseases, atopic dermatitis, and systemic lupus erythematosus through the regulation of T-cell populations and cytokine signaling.
- Other names
- Lactobacillus reuteri GMNL-89Lactobacillus plantarum GMNL-141Lactobacillus paracasei GMNL-133L. reuteri GMNL-89L. plantarum GMNL-141L. paracasei GMNL-133
02
Targets
TNFA (Tumor necrosis factor alpha (soluble))IL-6 (Interleukin 6)IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on lactobacillus reuteri gmnl-89 + lactobacillus plantarum gmnl-141 + lactobacillus paracasei gmnl-133.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus reuteri gmnl-89 + lactobacillus plantarum gmnl-141 + lactobacillus paracasei gmnl-133.